RATIONALE: Interpatient variability in montelukast response may be related to variation in leukotriene pathway candidate genes. OBJECTIVE: To determine associations between polymorphisms in leukotriene pathway candidate genes with outcomes in patients with asthma receiving montelukast for 6 mo who participated in a clinical trial. METHODS: Polymorphisms were typed using Sequenom matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass array spectrometry and published methods; haplotypes were imputed using single nucleotide polymorphism-expectation maximization (SNP-EM). Analysis of variance and logistic regression models were used to test for changes in outcomes by genotype. In addition, chi(2) and likelihood ratio tests were used to test for differences between groups. Case-control comparisons were analyzed using the SNP-EM Omnibus likelihood ratio test. MEASUREMENTS: Outcomes were asthma exacerbation rate and changes in FEV(1) compared with baseline. RESULTS: DNA was collected from 252 participants: 69% were white, 26% were African American. Twenty-eight SNPs in the ALOX5, LTA4H, LTC4S, MRP1, and cysLT1R genes, and an ALOX5 repeat polymorphism were successfully typed. There were racial disparities in allele frequencies in 17 SNPs and in the repeat polymorphism. Association analyses were performed in 61 whites. Associations were found between genotypes of SNPs in the ALOX5 (rs2115819) and MRP1 (rs119774) genes and changes in FEV(1) (p < 0.05), and between two SNPs in LTC4S (rs730012) and in LTA4H (rs2660845) genes for exacerbation rates. Mutant ALOX5 repeat polymorphism was associated with decreased exacerbation rates. There was strong linkage disequilibrium between ALOX5 SNPs. Associations between ALOX5 haplotypes and risk of exacerbations were found. CONCLUSIONS: Genetic variation in leukotriene pathway candidate genes contributes to variability in montelukast response.
RATIONALE: Interpatient variability in montelukast response may be related to variation in leukotriene pathway candidate genes. OBJECTIVE: To determine associations between polymorphisms in leukotriene pathway candidate genes with outcomes in patients with asthma receiving montelukast for 6 mo who participated in a clinical trial. METHODS: Polymorphisms were typed using Sequenom matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass array spectrometry and published methods; haplotypes were imputed using single nucleotide polymorphism-expectation maximization (SNP-EM). Analysis of variance and logistic regression models were used to test for changes in outcomes by genotype. In addition, chi(2) and likelihood ratio tests were used to test for differences between groups. Case-control comparisons were analyzed using the SNP-EM Omnibus likelihood ratio test. MEASUREMENTS: Outcomes were asthma exacerbation rate and changes in FEV(1) compared with baseline. RESULTS: DNA was collected from 252 participants: 69% were white, 26% were African American. Twenty-eight SNPs in the ALOX5, LTA4H, LTC4S, MRP1, and cysLT1R genes, and an ALOX5 repeat polymorphism were successfully typed. There were racial disparities in allele frequencies in 17 SNPs and in the repeat polymorphism. Association analyses were performed in 61 whites. Associations were found between genotypes of SNPs in the ALOX5 (rs2115819) and MRP1 (rs119774) genes and changes in FEV(1) (p < 0.05), and between two SNPs in LTC4S (rs730012) and in LTA4H (rs2660845) genes for exacerbation rates. Mutant ALOX5 repeat polymorphism was associated with decreased exacerbation rates. There was strong linkage disequilibrium between ALOX5 SNPs. Associations between ALOX5 haplotypes and risk of exacerbations were found. CONCLUSIONS: Genetic variation in leukotriene pathway candidate genes contributes to variability in montelukast response.
Authors: E S Silverman; S B Liggett; E W Gelfand; L J Rosenwasser; R M Baron; S Bolk; S T Weiss; J M Drazen Journal: Pharmacogenomics J Date: 2001 Impact factor: 3.550
Authors: Elliot Israel; Paul S Chervinsky; Bruce Friedman; Julius Van Bavel; Carol S Skalky; Asma F Ghannam; Steven R Bird; Jonathan M Edelman Journal: J Allergy Clin Immunol Date: 2002-12 Impact factor: 10.793
Authors: J M Drazen; C N Yandava; L Dubé; N Szczerback; R Hippensteel; A Pillari; E Israel; N Schork; E S Silverman; D A Katz; J Drajesk Journal: Nat Genet Date: 1999-06 Impact factor: 38.330
Authors: K H In; K Asano; D Beier; J Grobholz; P W Finn; E K Silverman; E S Silverman; T Collins; A R Fischer; T P Keith; K Serino; S W Kim; G T De Sanctis; C Yandava; A Pillari; P Rubin; J Kemp; E Israel; W Busse; D Ledford; J J Murray; A Segal; D Tinkleman; J M Drazen Journal: J Clin Invest Date: 1997-03-01 Impact factor: 14.808
Authors: Stanley J Szefler; Brenda R Phillips; Fernando D Martinez; Vernon M Chinchilli; Robert F Lemanske; Robert C Strunk; Robert S Zeiger; Gary Larsen; Joseph D Spahn; Leonard B Bacharier; Gordon R Bloomberg; Theresa W Guilbert; Gregory Heldt; Wayne J Morgan; Mark H Moss; Christine A Sorkness; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2005-02 Impact factor: 10.793
Authors: I Sayers; S Barton; S Rorke; J Sawyer; Q Peng; B Beghé; S Ye; T Keith; J B Clough; J W Holloway; A P Sampson; S T Holgate Journal: Clin Exp Allergy Date: 2003-08 Impact factor: 5.018
Authors: K M Giacomini; C M Brett; R B Altman; N L Benowitz; M E Dolan; D A Flockhart; J A Johnson; D F Hayes; T Klein; R M Krauss; D L Kroetz; H L McLeod; A T Nguyen; M J Ratain; M V Relling; V Reus; D M Roden; C A Schaefer; A R Shuldiner; T Skaar; K Tantisira; R F Tyndale; L Wang; R M Weinshilboum; S T Weiss; I Zineh Journal: Clin Pharmacol Ther Date: 2007-03 Impact factor: 6.875
Authors: Kelan G Tantisira; John Lima; Jody Sylvia; Barbara Klanderman; Scott T Weiss Journal: Pharmacogenet Genomics Date: 2009-03 Impact factor: 2.089